Last update 10 Dec 2024

Boric acid

Last update 10 Dec 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryBoric acid, as alias name as orthoboric acid, is a white, crystalline compound that is used for various purposes, including as an antiseptic, insecticide, and flame retardant . Also, It has been used for medical purposes for over 100 years and is available in many countries, including the United States. It is typically used as an antiseptic for minor cuts and burns, as well as for certain vaginal infections. Boric acid is also used in some prescription medications for the treatment of eye infections. It was first prepared by Wilhelm Homberg from borax, by the action of mineral acids, and was given the name sal sedativum Hombergi ("sedative salt of Homberg"). Its exact mechanism of action is not fully understood. But it is believed that boric acid works by disrupting the cell membranes of fungi and bacteria, leading to cell death. And It is important to note that boric acid can be toxic if ingested or absorbed through the skin in large amounts. Therefore, it should only be used as directed by a healthcare professional or as indicated on the product label.

Drug Type

Small molecule drug

Synonyms

hydrogen borate, orthoboric acid

Target-

Mechanism-

Therapeutic Areas

NeoplasmsInfectious DiseasesNervous System Diseases+ [2]

Active Indication-

Inactive Indication

Abortion, SpontaneousBacterial VaginosisCandidiasis+ [9]

Originator Organization

ChoA Pharmaceutical Co., Ltd.

Active Organization

ChoA Pharmaceutical Co., Ltd.

Inactive Organization

University of British Columbia

Bangalore Medical College & Research Institute

Drug Highest PhaseApproved

First Approval Date

US (30 Jun 2012)

Regulation-

Structure

Molecular FormulaBH3O3

InChIKeyKGBXLFKZBHKPEV-UHFFFAOYSA-N

CAS Registry10043-35-3

Clinical Trials associated with Boric acid

CTRI/2024/11/076440 / Not yet recruitingPhase 3IIT

Clinical evaluation of adjunctive use of boric acid as root biomodification agent in gingival recession coverage therapy-clinical trial - nil

Start Date11 Nov 2024

Sponsor / Collaborator-

RBR-7m7yjdj / RecruitingPhase 3IIT

Evaluation of the effectiveness of Boric Acid in otological bandage for treatment of infectious process in mastoid cavities: randomized and blind clinical study

Start Date24 Jun 2023

Sponsor / Collaborator-

CTRI/2022/01/039685 / CompletedNot ApplicableIIT

comparative evaluation of boric acid with chlorhexidine mouthwash in plaque induced gingivitis treatment- a double blind randomised controlled clinical trial

Start Date27 Jan 2022

Sponsor / Collaborator-

100 Clinical Results associated with Boric acid

100 Translational Medicine associated with Boric acid

100 Patents (Medical) associated with Boric acid

627

Literatures (Medical) associated with Boric acid

01 Dec 2024·OBSTETRICS AND GYNECOLOGY

Assessment and Treatment of Vaginitis.

Review

Author: Mitchell, Caroline M

Vaginitis is the presenting symptom at millions of office visits each year in the United States. Although treatment of sporadic cases is often straightforward, recurrent cases present both diagnostic and treatment challenges. Molecular diagnostic tests are likely superior to in-office microscopy for most clinicians and most cases. In both recurrent bacterial vaginosis and recurrent vulvovaginal candidiasis, national treatment guidelines recommend an extended treatment duration with one of the first-line agents. In cases in which such treatment is not successful, vaginal boric acid is likely the cheapest and easiest alternative option. New antifungal medications offer additional but limited treatment options. Probiotics are not recommended for prevention of vulvovaginal candidiasis; however, vaginal products containing Lactobacillus crispatus may have promise for recurrent bacterial vaginosis. Trichomoniasis should be treated with a 1-week course of metronidazole; this is the only sexually transmitted infection for which treatment recommendations vary by sex. In cases in which patients do not respond to initial treatment, the diagnosis should be reconsidered, and other potential causes such as desquamative inflammatory vaginitis, genitourinary syndrome of menopause, or vulvodynia should be considered.

01 Dec 2024·Biological trace element research

Effects of Boric acid as Maternal Feed Additives on the Development and Sex Ratio of Mouse pups

Article

Author: Aykal, M B ; Taskin, A C ; Gecin, M N ; Kar, F ; Sogut, I

Abstract:

Boron is primarily used in industrial applications, with recent interest revolving around its effects on metabolism. In this study, we administered boric acid (BA), which has positive effects on reproduction, in conjunction with feed supplementation to serve as a model for experimental animal development and breeding. The pregnancy performance, offspring development, and biochemical effects of mice given feed supplemented with BA at concentrations of 0 (control group), 250, and 500 ppm (BA groups) were investigated. A total of 18 female Balb-C mice were utilized for pregnancy. The mice were given the BA-supplemented feed during a period encompassing three weeks of pregnancy and three weeks of lactation. The numbers and weights of offspring born in cages on days 19–21 were determined. Blood and tissue samples were collected from the offspring during the third week postnatal, and the malondialdehyde (MDA) and total antioxidant and oxidant status (TAS, TOS, and OSI) levels were determined. A significant increase in female offspring was observed in the groups born to mice fed with BA compared to the control group. Positive development in organ weights was observed in the 250-ppm BA group. The 250-ppm group exhibited a significant increase in TAS compared to the control group, while TOS and MDA levels showed a decrease. Also, the levels of BA groups were found to decrease in both the OSI index serum and organ samples compared to the control group. Thus, the use of 250-ppm BA demonstrated positive effects on female offspring production, organ development, and antioxidant levels.

01 Dec 2024·Biological trace element research

Genome-Wide Screens Identify Genes Responsible for Intrinsic Boric Acid Resistance in Escherichia coli

Article

Author: Kürkçü, Merve Sezer ; Çöl, Bekir ; Di Bek, Esra

Abstract:

Boric acid (BA) has antimicrobial properties and is used to combat bacterial infections, including Enterobacteria. However, the molecular mechanisms and cellular responses to BA are still unknown. This genomics study aims to provide new information on the genes and molecular mechanisms related to the antimicrobial effect of BA in Escherichia coli. The Keio collection of E. coli was used to screen 3985 single-gene knockout strains in order to identify mutant strains that were sensitive or hypersensitive to BA at certain concentrations. The mutant strains were exposed to different concentrations of BA ranging from 0 to 120 mM in LB media. Through genome-wide screens, 92 mutants were identified that were relatively sensitive to BA at least at one concentration tested. The related biological processes in the particular cellular system were listed. This study demonstrates that intrinsic BA resistance is the result of various mechanisms acting together. Additionally, we identified eighteen out of ninety-two mutant strains (Delta_aceF, aroK, cheZ, dinJ, galS, garP, glxK, nohA, talB, torR, trmU, trpR, yddE, yfeS, ygaV, ylaC, yoaC, yohN) that exhibited sensitivity using other methods. To increase sensitivity to BA, we constructed double and triple knockout mutants of the selected sensitive mutants. In certain instances, engineered double and triple mutants exhibited significantly amplified effects. Overall, our analysis of these findings offers further understanding of the mechanisms behind BA toxicity and intrinsic resistance in E. coli.

News (Medical) associated with Boric acid

14 Mar 2024

·www.fda.gov

FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors

UPDATE (Jan. 8, 2024): FDA is aware that some providers, including hospital or health-system pharmacies, may be preparing other STS products for patient use in place of Pedmark, including diluting STS products approved for other uses to match Pedmark’s strength. FDA reminds health care providers that as stated in Pedmark’s prescribing information, Pedmark is not substitutable with other sodium thiosulfate products. Such substitutions, pose potential health risks including: Potassium chloride exposure which, at high doses, can lead to increased risk of acute cardiac events and other serious adverse reactions. Potassium chloride is not present in Pedmark. Overexposure to boric acid (a boron compound), can cause health risks including headache, hypothermia, restlessness, weariness, renal injury, dermatitis, alopecia, anorexia and indigestion. Although Pedmark also contains boric acid, it is at a lower concentration than other STS products. Overexposure to sodium nitrite, which can lead to health risks including methemoglobinemia. Sodium nitrite is copackaged with sodium thiosulfate as a separate vial in some products; it is not present in Pedmark. On September 20, 2022, the Food and Drug Administration approved sodium thiosulfate (Pedmark, Fennec Pharmaceuticals Inc.) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors. Efficacy was evaluated in two multicenter open-label, randomized controlled trials in pediatric patients undergoing treatment with cisplatin-based chemotherapy for cancer: SIOPEL 6 (NCT00652132) and COG ACCL0431 (NCT00716976). SIOPEL 6 enrolled 114 patients with standard risk hepatoblastoma undergoing 6 cycles of perioperative cisplatin-based chemotherapy. Patients were randomized (1:1) to receive cisplatin-based chemotherapy with or without sodium thiosulfate administered at various doses of 10 g/m2, 15 g/m2, or 20 g/m2 based on actual body weight. The primary outcome was the percentage of patients with Brock Grade ≥1 hearing loss, assessed using pure tone audiometry after treatment or at an age of at least 3.5 years, whichever was later. The incidence of hearing loss was lower in the sodium thiosulfate and cisplatin arm (39%) compared with the cisplatin alone arm (68%); unadjusted relative risk 0.58 (95% CI: 0.40, 0.83). COG ACCL0431 enrolled 125 pediatric patients with solid tumors undergoing a chemotherapy regimen including cumulative cisplatin doses of 200 mg/m2 or higher, with individual cisplatin doses to be infused over 6 hours or less. Patients were randomized (1:1) to receive cisplatin-based chemotherapy with or without sodium thiosulfate. Efficacy was evaluated in a subset of 77 patients with localized, non-metastatic solid tumors. The primary outcome was hearing loss according to American Speech-Language-Hearing Association (ASHA) criteria, assessed at baseline and 4-weeks after the final course of cisplatin. The incidence of hearing loss was lower in the sodium thiosulfate and cisplatin arm (44%) compared with the cisplatin alone arm (58%); unadjusted relative risk 0.75 (95% CI: 0.48, 1.18). The most common adverse reactions in the two trials (≥25% with difference between arms of >5% compared to cisplatin alone) were vomiting, nausea, decreased hemoglobin, hypernatremia, and hypokalemia. The recommended sodium thiosulfate dose is based on surface area according to actual body weight. Sodium thiosulfate is administered as an intravenous infusion over 15 minutes following cisplatin infusions that are 1 to 6 hours in duration. View full prescribing information for Pedmark. This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The application also was granted Orphan Drug designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. For information on the COVID-19 pandemic, see the following resources: FDA: Coronavirus Disease 2019 (COVID-19) NCI: Coronavirus: What People With Cancer Should Know CDC: Coronavirus (COVID-19) Follow the Oncology Center of Excellence on Twitter @FDAOncology

Clinical ResultOrphan Drug

01 Feb 2024

·www.biospace.com

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a public reminder to healthcare providers that PEDMARK (sodium thiosulfate injection) is not substitutable with other sodium thiosulfate products as explicitly directed in its prescribing label. PEDMARK is the first and only FDA approved therapy indicated to reduce the risk of ototoxicity (e.g., permanent hearing loss) associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. The FDA stated in the public communication that it is aware that some providers may be preparing other sodium thiosulfate (STS) products for patient use in place of PEDMARK, including diluting STS products approved for other uses to match the strength of PEDMARK. The FDA reminded health care providers that as stated in PEDMARK’s prescribing information, PEDMARK is not substitutable with other sodium thiosulfate products. The FDA stated that such substitutions pose potential health risks, including: Potassium chloride exposure which, at high doses, can lead to increased risk of acute cardiac events and other serious adverse reactions. Potassium chloride is not present in PEDMARK. Overexposure to boric acid (a boron compound), can cause health risks including headache, hypothermia, restlessness, weariness, renal injury, dermatitis, alopecia, anorexia and indigestion. Although PEDMARK also contains boric acid, it is at a lower concentration than other STS products. Overexposure to sodium nitrite, which can lead to health risks including methemoglobinemia. Sodium nitrite is co-packaged with sodium thiosulfate as a separate vial in some products; it is not present in PEDMARK. The public communication was issued by the FDA’s Professional Affairs and Stakeholder Engagement Staff within the Center for Drug Evaluation and Research, Office of Communications. The FDA encourages those with any questions to contact FDAOncology@fda.hhs.gov. About Fennec Pharmaceuticals Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® and Pedmarqsi to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission Marketing Authorization in June 2023 for Pedmarqsi. PEDMARK has received Orphan Drug Exclusivity in the U.S. for seven years of market protection and Pedmarqsi has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit . Investors: Robert Andrade Chief Financial Officer Fennec Pharmaceuticals Inc. +1 919-246-5299 Corporate and Media: Lindsay Rocco Elixir Health Public Relations +1 862-596-1304 lrocco@elixirhealthpr.com

Orphan DrugLicense out/inDrug Approval

04 Dec 2023

·www.sciencedaily.com

Sugar permeation discovered in plant aquaporins

Aquaporins, which move water through membranes of plant cells, were not thought to be able to permeate sugar molecules, but researchers have observed sucrose transport in plant aquaporins for the first time, challenging this theory. Aquaporins, which move water through membranes of plant cells, were not thought to be able to permeate sugar molecules, but University of Adelaide researchers have observed sucrose transport in plant aquaporins for the first time, challenging this theory. The finding, made by researchers from the School of Agriculture, Food and Wine, widens the concept of aquaporins' role in plant biology and will have implications for the bioengineering of plants for food production and plant survival. Aquaporins, which belong to a class of membrane proteins known as water-transporters, were first identified in 1993 by American molecular biologist and Nobel Laureate, Peter Agre. The concept of water-permeation in small molecules was accepted at the time, but it was unclear if aquaporins could permeate larger molecules, such as sucrose. This has now been demonstrated, with researchers employing a multidisciplinary approach to observe the biochemical process in HvNIP2;1, which is a Nodulin 26-like Intrinsic Protein found in barley. "We used nanobiotechnology, electrophysiology, protein chemistry, protein modelling and computational chemistry. We also integrated vast experimental and theoretical data with phylogenomics exploring around 3,000 aquaporins," said the University of Adelaide's Professor Maria Hrmova. HvNIP2;1 is different from other sub-clades of aquaporins in that it has altered structural characteristics and thus it acquired the ability to transport saccharides. Researchers are interested to see what other functions it may serve and how this relates to in planta function. "We also performed full-scale steered molecular dynamics simulations of HvNIP2;1 and a spinach aquaporin -- a structurally and functionally divergent aquaporin compared to HvNIP2;1 -- revealing potential rectification of water, boric acid, and sucrose. This will be the subject of future studies," said Professor Hrmova. The discovery has been published in the Journal of Biological Chemistry, a forum for fundamental research at the intersection of biochemistry, biophysics and biology, and demonstrates the importance of questioning assumed knowledge. "This work exemplifies that we need to be more open-minded about what different aquaporins may permeate, besides water," said the paper's co-author, Professor Steve Tyerman, who previously revealed ion permeation in plant aquaporins. "Water may be secondary to other important molecules in aquaporins, or some may be co-transport water and other molecules by virtue of a vast array of protein-ligand interactions," said Professor Hrmova. Understanding the properties of aquaporins is important for bioengineering to design novel proteins with improved characteristics, such as substrate specificity, thermostability, and folding. These properties are fundamental to the survival of plants as they mediate water and nutrient uptake, govern the distribution of solutes through plants, remove toxins from the cytosol, and recycle valuable sugars. Given their gatekeeping functions, aquaporins and other membrane transporters are attractive targets in agricultural biotechnology for increasing nutrient contents in edible parts of crop plants, excluding toxic elements, which together directly affect crop quality and ultimately sustained production of our food.

100 Deals associated with Boric acid

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cerebral Palsy	Phase 3	IN	Bangalore Medical College & Research Institute	31 Jul 2015
Chronic Periodontitis	Phase 3	IN	Bangalore Medical College & Research Institute	31 Jul 2015
Furcation Defects	Phase 3	IN	Bangalore Medical College & Research Institute	31 Jul 2015
Abortion, Spontaneous	Phase 3	CA	University of British Columbia	30 Apr 2014
Candidiasis	Phase 3	CA	University of British Columbia	30 Apr 2014
Cysts	Phase 3	CA	University of British Columbia	30 Apr 2014
Endometritis	Phase 3	CA	University of British Columbia	30 Apr 2014
Gonorrhea	Phase 3	CA	University of British Columbia	30 Apr 2014
Secondary infection	Phase 3	CA	University of British Columbia	30 Apr 2014
Surgical Wound Infection	Phase 3	CA	University of British Columbia	30 Apr 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis